Study analysis · Food & function · 2024
Eating one avocado a day may boost your gut bacteria—but only if your diet is already poor, and the effect is tiny.
A 6-month study found that daily avocado consumption slightly increased gut microbiome diversity in people with belly fat, especially those with low diet quality, but didn't change most health markers.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study randomly assigned people to eat an avocado daily or not, so it's a strong type of study for testing cause and effect. But it's a side study looking at gut bacteria, not the main health outcomes, and many stool samples were missing later on, so we can only say avocado 'may' or 'likely' change gut bacteria, not that it definitely does or that it makes people healthier.
What’s the bottom line?
Adults with abdominal obesity ate one avocado per day for 26 weeks or kept their usual diet. The avocado group had slightly more diverse gut bacteria.
How strong is this study?
The study was well-designed because it randomly put people into groups and followed them for six months, which helps make the comparison fair. However, people knew if they were eating avocados, and many stool samples were lost by the end, so the results are less certain than they could be.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
73 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=230)+13.7/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 579 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Randomized controlled trial design supports causal inference for intervention effects, but this ancillary analysis has unknown blinding, no placebo control (habitual diet), high attrition of fecal samples at week 26 (41% missing), exploratory outcomes, and multiple comparisons. These factors reduce certainty; causal claims should be tempered.
COI Unknown
Could not determine conflict of interest status
The provided excerpt includes links to 'Conflicts of interest' and 'Acknowledgements' sections but does not contain their content. Therefore, conflicts of interest and funding sources cannot be assessed from the available text.
Author affiliations are all academic or medical institutions; no industry affiliations are listed. The study title indicates an ancillary study of the HAT randomized controlled trial, which may have industry funding not disclosed in this excerpt.
Key takeaways
- 01
Chao1 diversity increased at week 4 (p=0.03) and week 26 (p=0.004).
- 02
Shannon diversity increased at week 26 (p=0.02).
- 03
Beta diversity differed at week 26 (R2=0.002, p=0.02; about 0.2% of variance explained).
- 04
Faecalibacterium prausnitzii and Bacterium AF16_15 increased at week 26 (q<0.25).
- 05
No metabolic pathways were significant after correction.
- 06
No absolute risk increase was reported because outcomes are microbiome measures, not clinical events.
- 07
For a person, eating an avocado daily may slightly shift gut bacteria, especially if baseline diet quality is poor.
- 08
The average effect was small: treatment explained about 0.2% of community variation at week 26, and individual variability was large.
- 09
Most metabolic markers did not change, so absolute clinical benefit is unclear and not reported.
Surprising findings
- The effect of avocado on gut microbiome was more pronounced in people with poor baseline diets.We might expect everyone to benefit equally from a healthy food, but this suggests that those with poorer diets have more room for improvement.
- No metabolic pathways differed significantly after FDR correction, despite taxonomic changes.Even though the types of bacteria changed, their functional capacity (what they do) did not change significantly, suggesting redundancy in the microbiome.
- Participant factors explained 65% of the variation in gut microbiome composition, while avocado intervention explained only 0.2%.It highlights that personal factors like age, gender, and genetics are far more influential than a single dietary change.
Practical takeaways
If you have a poor diet and want to improve gut health, consider adding an avocado daily—but focus on overall diet quality.
The effect is small, and this study doesn't prove causation for health outcomes. Also, the high attrition may limit generalizability.
Medium (RCT but ancillary, high attrition, industry funding) confidenceDon't rely on avocado alone to improve cholesterol or metabolic health; other lifestyle factors matter more.
Only HDL improved in a subgroup; most markers didn't change. Long-term effects unknown.
Medium confidenceFor gut health, diversify your diet rather than focusing on single foods.
This study only tested avocado; other fiber-rich foods may have similar effects.
High (general nutrition principle) confidenceWhy this study matters
Avocado's gut benefits only for poor diets
In a 26-week RCT, daily avocado consumption increased gut alpha diversity (Chao1 p=0.004 at week 26) compared to habitual diet. However, this effect was significant only in participants with low baseline diet quality (HEI ≤52.7). In the high diet quality group, no significant changes were observed.
This suggests that avocados may act as a 'prebiotic' specifically for those who need it most—people with poor diets. It's a personalized nutrition angle.
Tiny effect size: avocado explains 0.2% of gut variation
Beta diversity analysis showed a significant but very small difference between groups at week 26 (R2=0.002, p=0.02), meaning avocado consumption explained only about 0.2% of the variation in microbial community composition. Individual factors like age, gender, and race explained much more (R2=0.65).
People often overestimate the impact of single foods. This highlights that gut microbiome is largely personal and that no single food is a magic bullet.
Avocado boosts butyrate-producing bacteria
At week 26, the avocado group had significantly higher relative abundance of Faecalibacterium prausnitzii and Bacterium AF16_15 (q<0.25). F. prausnitzii is a major butyrate producer associated with gut health and reduced inflammation.
Butyrate is a short-chain fatty acid that feeds colon cells and has anti-inflammatory effects. This could be a mechanism for avocado's health benefits.
No metabolic improvements, except HDL in poor diet group
Most anthropometric and biochemical measures (BMI, visceral fat, glucose, insulin, inflammatory markers, cholesterol) did not change significantly with avocado consumption. Only HDL cholesterol improved in the low diet quality subgroup (p=0.0008).
This challenges the idea that avocado improves heart health markers in the short term. It suggests that gut changes may not translate to clinical benefits quickly.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Adults with abdominal obesity ate one avocado per day for 26 weeks or kept their usual diet. The avocado group had slightly more diverse gut bacteria.
Research results
Chao1 diversity increased at week 4 (p=0.03) and week 26 (p=0.004). Shannon diversity increased at week 26 (p=0.02). Beta diversity differed at week 26 (R2=0.002, p=0.02; about 0.2% of variance explained). Faecalibacterium prausnitzii and Bacterium AF16_15 increased at week 26 (q<0.25). No metabolic pathways were significant after correction. No absolute risk increase was reported because outcomes are microbiome measures, not clinical events.
What this means - more context
For a person, eating an avocado daily may slightly shift gut bacteria, especially if baseline diet quality is poor. The average effect was small: treatment explained about 0.2% of community variation at week 26, and individual variability was large. Most metabolic markers did not change, so absolute clinical benefit is unclear and not reported.
Purpose: investigate short-term and long-term impact of daily avocado consumption without caloric restriction on gut microbiota in free-living adults with abdominal obesity. Ancillary study of the HAT randomized controlled trial. Not retracted; no corrections reported.
In this 26-week ancillary RCT (n=230 analyzed from UCLA site), one avocado/day vs habitual diet increased gut alpha diversity (Chao1 week 4 p=0.03, week 26 p=0.004; Shannon week 26 p=0.02) and shifted beta diversity at week 26 (R2=0.002, p=0.02; absolute variance explained about 0.2%). Faecalibacterium prausnitzii and Bacterium AF16_15 increased at week 26 (q<0.25). No metabolic pathways survived FDR. Effects were more pronounced in the low baseline HEI (≤52.7) subgroup. Most anthropometric and biochemical measures did not change.
Methods Used
Multicenter RCT; 1008 adults with abdominal obesity randomized to AVO (one Hass avocado/day) or HAB for 26 weeks. Ancillary fecal subset from UCLA site (n=230; complete baseline/week4/week26 samples n=141). Shotgun metagenomics; alpha diversity Chao1/Shannon; beta diversity Bray-Curtis PERMANOVA; MaAsLin2 differential abundance; linear mixed models; mediation analysis.
Main Finding
Primary outcome: daily avocado increased alpha diversity vs habitual diet (Chao1 week 4 p=0.03, week 26 p=0.004; Shannon week 26 p=0.02) and changed beta diversity at week 26 (R2=0.002, p=0.02; absolute variance explained about 0.2%). Species increases included Faecalibacterium prausnitzii and Bacterium AF16_15 at week 26 (q<0.25). Effects were more pronounced in low HEI subgroup. No significant metabolic pathway differences after FDR. Absolute clinical risk not applicable/reported.
Confidence Level
Moderate. Randomized controlled trial but ancillary subset with high week-26 fecal sample attrition (41%), small effect sizes and large individual variability; no functional pathway differences survived FDR; industry funding/COI disclosed. Findings in low HEI subgroup are exploratory.
Study Flags
Red Flags
- •High week-26 fecal sample attrition (41% in both groups)
- •Small effect sizes (e.g., beta diversity R2=0.002) and large individual variability
- •Industry funding from Avocado Nutrition Center and disclosed conflict of interest
Surprising Findings
The effect of avocado on gut microbiome was more pronounced in people with poor baseline diets.
We might expect everyone to benefit equally from a healthy food, but this suggests that those with poorer diets have more room for improvement.
Practical Takeaways
If you have a poor diet and want to improve gut health, consider adding an avocado daily—but focus on overall diet quality.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 579 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study randomly assigned people to eat an avocado daily or not, so it's a strong type of study for testing cause and effect. But it's a side study looking at gut bacteria, not the main health outcomes, and many stool samples were missing later on, so we can only say avocado 'may' or 'likely' change gut bacteria, not that it definitely does or that it makes people healthier.
Strengths
- Randomized controlled trial design with control group.
- Large parent trial (n=1008); ancillary sample n=230 for microbiome.
- Longitudinal repeated sampling at baseline, week 4, and week 26.
Weaknesses
- Blinding status unknown; participants likely aware of avocado assignment.
- No placebo or isocaloric control; control group maintained habitual diet.
- High fecal sample attrition at week 26 (41% missing).
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Adults with abdominal obesity ate one avocado per day for 26 weeks or kept their usual diet. The avocado group had slightly more diverse gut bacteria.
Research results
Chao1 diversity increased at week 4 (p=0.03) and week 26 (p=0.004). Shannon diversity increased at week 26 (p=0.02). Beta diversity differed at week 26 (R2=0.002, p=0.02; about 0.2% of variance explained). Faecalibacterium prausnitzii and Bacterium AF16_15 increased at week 26 (q<0.25). No metabolic pathways were significant after correction. No absolute risk increase was reported because outcomes are microbiome measures, not clinical events.
What this means - more context
For a person, eating an avocado daily may slightly shift gut bacteria, especially if baseline diet quality is poor. The average effect was small: treatment explained about 0.2% of community variation at week 26, and individual variability was large. Most metabolic markers did not change, so absolute clinical benefit is unclear and not reported.
Purpose: investigate short-term and long-term impact of daily avocado consumption without caloric restriction on gut microbiota in free-living adults with abdominal obesity. Ancillary study of the HAT randomized controlled trial. Not retracted; no corrections reported.
In this 26-week ancillary RCT (n=230 analyzed from UCLA site), one avocado/day vs habitual diet increased gut alpha diversity (Chao1 week 4 p=0.03, week 26 p=0.004; Shannon week 26 p=0.02) and shifted beta diversity at week 26 (R2=0.002, p=0.02; absolute variance explained about 0.2%). Faecalibacterium prausnitzii and Bacterium AF16_15 increased at week 26 (q<0.25). No metabolic pathways survived FDR. Effects were more pronounced in the low baseline HEI (≤52.7) subgroup. Most anthropometric and biochemical measures did not change.
Methods Used
Multicenter RCT; 1008 adults with abdominal obesity randomized to AVO (one Hass avocado/day) or HAB for 26 weeks. Ancillary fecal subset from UCLA site (n=230; complete baseline/week4/week26 samples n=141). Shotgun metagenomics; alpha diversity Chao1/Shannon; beta diversity Bray-Curtis PERMANOVA; MaAsLin2 differential abundance; linear mixed models; mediation analysis.
Main Finding
Primary outcome: daily avocado increased alpha diversity vs habitual diet (Chao1 week 4 p=0.03, week 26 p=0.004; Shannon week 26 p=0.02) and changed beta diversity at week 26 (R2=0.002, p=0.02; absolute variance explained about 0.2%). Species increases included Faecalibacterium prausnitzii and Bacterium AF16_15 at week 26 (q<0.25). Effects were more pronounced in low HEI subgroup. No significant metabolic pathway differences after FDR. Absolute clinical risk not applicable/reported.
Confidence Level
Moderate. Randomized controlled trial but ancillary subset with high week-26 fecal sample attrition (41%), small effect sizes and large individual variability; no functional pathway differences survived FDR; industry funding/COI disclosed. Findings in low HEI subgroup are exploratory.
Study Flags
Red Flags
- •High week-26 fecal sample attrition (41% in both groups)
- •Small effect sizes (e.g., beta diversity R2=0.002) and large individual variability
- •Industry funding from Avocado Nutrition Center and disclosed conflict of interest
Surprising Findings
The effect of avocado on gut microbiome was more pronounced in people with poor baseline diets.
We might expect everyone to benefit equally from a healthy food, but this suggests that those with poorer diets have more room for improvement.
Practical Takeaways
If you have a poor diet and want to improve gut health, consider adding an avocado daily—but focus on overall diet quality.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 579 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study randomly assigned people to eat an avocado daily or not, so it's a strong type of study for testing cause and effect. But it's a side study looking at gut bacteria, not the main health outcomes, and many stool samples were missing later on, so we can only say avocado 'may' or 'likely' change gut bacteria, not that it definitely does or that it makes people healthier.
Strengths
- Randomized controlled trial design with control group.
- Large parent trial (n=1008); ancillary sample n=230 for microbiome.
- Longitudinal repeated sampling at baseline, week 4, and week 26.
Weaknesses
- Blinding status unknown; participants likely aware of avocado assignment.
- No placebo or isocaloric control; control group maintained habitual diet.
- High fecal sample attrition at week 26 (41% missing).
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study was well-designed because it randomly put people into groups and followed them for six months, which helps make the comparison fair. However, people knew if they were eating avocados, and many stool samples were lost by the end, so the results are less certain than they could be.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
73 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=230)+13.7/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 579 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Randomized controlled trial design supports causal inference for intervention effects, but this ancillary analysis has unknown blinding, no placebo control (habitual diet), high attrition of fecal samples at week 26 (41% missing), exploratory outcomes, and multiple comparisons. These factors reduce certainty; causal claims should be tempered.
COI Unknown
Could not determine conflict of interest status
The provided excerpt includes links to 'Conflicts of interest' and 'Acknowledgements' sections but does not contain their content. Therefore, conflicts of interest and funding sources cannot be assessed from the available text.
Author affiliations are all academic or medical institutions; no industry affiliations are listed. The study title indicates an ancillary study of the HAT randomized controlled trial, which may have industry funding not disclosed in this excerpt.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Thomas DeLauer cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
17 researchersIf this is your work, this is how we attribute it on Fit Body Science. Jieping Yang is listed as the lead author.